sues like limited 24/7 surgical coverage and access to operating theaters and anesthetic and nursing staff. 34 Recognizing risk factors for aneurysmal rebleeding is particularly relevant and might help to identify the aneurysms that benefit from acute treatment. In recent years, several risk factors, such as hypertension and the location and size of the aneurysm, have been shown to be associated with rebleeding. 9, 10, 19, 28, 37 Biomechanical studies have indicated that cerebral aneurysmal rupture occurs when there is a decrease in the ratio of the artery wall thickness to the radius of the aneurysm. 7 This concept might explain the possible relationship between aneurysm diameter and the risk of rebleeding. However, the association between the risk of rebleeding and aneurysm size might be confounded by age. 28 In particular, older patients may have larger aneurysms, and their general condition makes it more likely that treatment is postponed, leaving these individuals more prone to rebleeding. This meta-analysis was performed to evaluate whether an association could be established between aneurysm diameter and rebleeding rate before treatment. Potentially confounding factors like age, aneurysm location, and the presence of hypertension were also evaluated.
methods search strategy and selection criteria
The meta-analysis was constructed using the MOOSE guidelines. 38 In particular, an independent, experienced librarian systematically searched the PubMed, Embase, and Cochrane databases up to April 3, 2013 , for studies of patients with aneurysmal SAH that reported the association between aneurysm diameter and pretreatment aneurysmal rebleeding. The search strategy is set out in Table 1 .
data extraction
Two authors (J.V.L. and H.B.) independently read all titles and abstracts and selected those that appeared to be relevant for a full text review without language restrictions. Conference abstracts, reviews, meta-analyses, editorials, and animal studies were excluded. From the remaining studies, full-text articles were obtained and independently evaluated by two of the authors (J.V.L. and H.B.). Studies were deemed to be eligible if they included: 1) patients with SAH in either a prospective or retrospective population-based design; 2) the association between aneurysm diameter and the rebleeding rate; and 3) results that included or enabled the calculation of an odds ratio. A third author (R.B.) was consulted to resolve any disagreements. Reference screening was conducted to identify additional studies from the full-text articles that were evaluated. Included studies were selected for a quality review. The methods recommended by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for rating the quality of evidence were applied. 2, [11] [12] [13] [14] [15] [16] [17] The ORs and 95% CIs between small and large intracranial aneurysms were extracted or calculated. Size categories were then registered. The cutoff between small and large size had to be established according to the published data. In cases of overlapping cohorts, we excluded the one with the lesser-quality data or, if equal in quality, the one with the fewest patients to prevent an artificial increase in effect size.
statistical analysis
Comprehensive Meta-Analysis software (Version 2.2.046, 2007, Biostat, Inc.) was used to perform statistical analysis. The odds ratio for the risk of the rebleeding of small compared with large intracranial aneurysms was used as the effect size. Size cutoff was determined based on the presence of a (close to) common value across the studies. Both fixed-and random-effect models were used to calculate the summary ORs and 95% CIs. The significance of the overall OR was determined using a Z-test. For the sensitivity analysis, each study was removed from the total and the remaining studies were reanalyzed. The Type I error was set at 0.05 and the tests were 2-tailed. We assessed the heterogeneity between the study estimates using the I 2 statistic, with thresholds for a low degree of heterogeneity set at 40%. 13 The funnel plots were inspected, and the Egger test was used to look for evidence of publication bias. 
results included studies
The literature search revealed a total of 1408 records: 610 in PubMed, 773 in Embase, and 25 in the Cochrane database ( Fig. 1 , Table 1 ). An additional study was found by screening the references. After the removal of duplicates, we were able to identify 867 studies. Review of the abstracts left us with 26 studies for the full-text evaluation. [3] [4] [5] [6] 9, 10, [18] [19] [20] [22] [23] [24] [25] [27] [28] [29] [30] [31] 33, [35] [36] [37] 39, 41 Ten studies were excluded because they did not evaluate aneurysm diameter as a risk factor for rehemorrhage rate. 4, 6, 9, 18, 22, 24, 29, 36, 39, 41 Two other articles were excluded because one was a review and the other was an editorial. 25, 36 One study was written in Japanese and was thus also excluded. 31 Four studies used an overlapping cohort, and the one with most appropriate data was selected. 5, 19, 20, 27, 28, 30, 35 In total we identified 9 studies that met our inclusion criteria. 3, 10, 19, 23, 27, 28, 33, 37, 41 Clinical and/or radiological definitions of rebleeding were given in 8 studies and these are listed in Table 2 . Only 1 study reported the median time to rebleeding and the median time to aneurysm repair. 3 Aneurysm size categories were given in 7 studies, while 2 others reported the mean size for the lesions in the non-rebleeding group compared with the rebleeding group (Table 2 ). Four studies reported on time to treatment or time to rebleeding ( Table 2) .
Quality assessment
The methodological quality of the 9 included studies was assessed. Of a total of 45 scores, there was no disagreement ( Table 3) . As a consequence of their observational design, all of the studies started with a maximal quality score of low. None of the studies were rated down based on serious inconsistency, indirectness, imprecision, or publication bias. In 5 studies, however, the quality was rated down because of serious limitations: Adjustment of the rebleeding rate for the time after the initial hemorrhage was not performed, or consecutive series were not reported. 10, 19, 23, 33, 37 data analysis Seven of 9 studies provided core data, making calculation of the OR possible. 10, 19, 23, 28, 33, 37, 41 Almost all of the studies used 10 mm as the cutoff point for aneurysm size among others classes, with only 1 study using 7 mm ( Table 4 ). An analysis was performed with this best unifiable cutoff point. Overall rebleeding occurred in 360 (17.0%) of 2121 patients (incidence range, from study to study, 8.7%-28.4%). The rate of rebleeding in small and large aneurysms was 14.0% and 23.6%, respectively (absolute risk difference 9.6%). The meta-analysis of the 7 studies revealed that larger size aneurysms had an overall OR for rebleeding of 2.32 (95% CI 1.77-3.04; p = 0.00) and an OR of 2.56 (95% CI 1.62-4.06; p = 0.00) for a fixed-and a random-effect model, respectively (Fig. 2 upper) . The results were subject to heterogeneity, which was determined by the I 2 statistic to be 60%, indicating that the random-effect model is appropriate. The sensitivity analysis did not alter the results (Fig. 2 lower) . The funnel plot gave no indication of publication bias, but the findings are of limited value because of the small number of studies considered (Fig.  3) . The Egger regression test revealed an intercept of 2.3 with a 2-tailed p value of 0.22, and it was accordingly not statistically significant. Five of the 7 studies reported data on age; 4 studies provided age-adjusted results and identified a persistent relationship between size and the risk of rebleeding. 10, 19, 28, 37 The presence of hypertension was reported in 2 studies and was more prevalent in patients with rebleeding in 1 of these studies. 10, 19 Location (anterior vs posterior circulation) was reported in 5 studies, while in 4 there was no difference in the rebleeding rate. 10, 19, 33, 37, 41 One study identified a lower risk of rebleeding associated with posterior circulation aneurysms. 37 These findings provide insufficient evidence to relate hypertension and/or location of the aneurysm with the rebleeding rate.
Only a single study evaluated the risk of rebleeding over time dichotomized for size; the authors found a difference of rebleeding rate within 24 hours that persisted for 3 days after the initial hemorrhage. 28 They reported a hazard ratio for large aneurysm of 2.4 (95% CI 1.2-4.5). In another study, median time to aneurysm obliteration did not differ between rebleeding and non-rebleeding groups but was not stratified according to lesion size. 3 The use of antifibrinolytic agents was reported only by 1 study; the investigators included patients from 1996 to 2011, and from 2003 on, they used, on a routine basis, aminocaproic acid for all patients before aneurysm clipping or coiling. 27 Conflicting results have been reported regarding the effect of clinical grade on the risk of rebleeding. Six studies evaluated Hunt and Hess grade as a factor in relation to rebleeding. One study matched for Hunt and Hess grade found a significant difference in aneurysm size in those with rebleeding versus those without rebleeding. 27 Two studies reported no significant association between Hunt and Hess grade and rebleeding risk. 32, 40 The authors of one study concluded that the larger the aneurysm, the worse was the World Federation of Neurosurgical Societies grade, but did not report it as a independent risk factor. 14 Two studies found Hunt and Hess grade to be a statistically significant independent risk factor for rebleeding (ORs 2.5 and 4.9). 5, 7 Clinical grade at admission is a possible independent risk factor for rebleeding.
discussion
The findings of this meta-analysis show that aneurysm size is an important determinant of aneurysmal rebleeding. Age and location are unlikely to be confounding factors. The presence of hypertension was insufficiently registered to determine the role of possible confounding effects. To reduce rebleeding rates, patients with large aneurysms should, when feasible, undergo acute treatment rather than ultra-early treatment, despite possible logistical issues. Additionally, if patients are referred from other centers, or if the diagnosis is delayed, those with large aneurysms still require urgent treatment because it has been shown that the effect size of this association might persist for up to 72 hours after the initial bleed. 28 An increased risk is seen even within 24 or 48 hours, the time window in which most aneurysm are currently treated. 25 The results of this analysis for ruptured aneurysms correspond with those of the ISUIA study, in which the pri- mary bleeding risk was greater for individuals with larger unruptured aneurysms. 40 The present research has several limitations. First, there is a potential for publication bias; studies showing no association between aneurysm diameter and rebleeding rate are less likely to be published. The estimated effect size in this meta-analysis could therefore be overestimated. Second, the studies considered did not include data from patients who had died before hospital admission, and this rate would be estimated to be as high as 15%. 26 Rebleeding rates during transfer to the hospital were also included and may be as high as 24%. 10 Moreover, the average time to hospital admission varied considerably after the initial SAH. Only one study reported median time to aneurysm repair and aneurysm rebleeding. 10 The research by Machiel Pleizier et al. revealed that there is no significant difference between small and large aneurysms when it comes to the risk of rebleeding 72 hours after the initial SAH. 28 Third, only one study reported the use of aminocaproic acid. 27 Although antifibrinolytic therapy does not improve survival or the chance of being independent in activities of daily living, it does reduce the risk of rebleeding by approximately 35%, as indicated in a recent Cochrane review. 1 Therefore, it is an important factor in rebleeding rate; unfortunately, the published studies did not provide data with which to evaluate the effects of both size and antifibrinolytic therapy together. Fourth, the cutoff for aneurysm size at 10 mm is artificial and chosen based on the categories set out in the published literature. Fifth, even if rebleeding is prevented in patients with large aneurysms, there is still a substantial rate of rebleeding events (14.0%) in cases involving small aneurysms. Only the acute treatment of all patients is optimal for prevention of rebleeding. 28 Hypothetically, acute treatment could be associated with additional treatment risks like increased intraoperative rupture due to the newly formed instable thrombus. However, for treatment within 24 hours, it has been shown that this timeframe was associated with improved clinical outcomes, although the benefit was more pronounced for coiling than clipping. 34 Moreover, it is unlikely that the risks of acute treatment will accrue in such a way that they outweigh the very high morbidity and mortality rates associated with rebleeding.
conclusions
This meta-analysis showed that aneurysm size is an important risk factor for aneurysmal rebleeding and should be used in the clinical risk assessment of individual patients. Our results confirmed the current guidelines and stressed the importance of acute treatment for large ruptured aneurysms.
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